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In a case–control study nested within the EPIC-Oxford cohort, there were no statistically significant differences in the prevalence or
titre of antibodies against BK virus measured in plasma taken prior to diagnosis between cases with cancer of the prostate (n¼31),
kidney (n¼5) or bladder (n¼9) and controls (n¼45).
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The BK virus (BKV), a human polyomavirus, is an important cause
of nephropathy and graft failure in immunosuppressed renal
transplant recipients (Kwak et al, 2002). In Western populations,
90–100% of people have antibodies against BKV by the age of 10
years. Latent infection is established in renal epithelial cells and
possibly in other tissues. The virus is oncogenic in newborn
hamsters and can transform mammalian cells in vitro, but there is
little consistent evidence of a link with human cancer. In a
previous study, the titre of antibodies against BKV was found to be
significantly higher among cases with prostate cancer than among
controls, although the finding was based on only 11 cases and
could have arisen by chance (Newton et al, in press). Alternatively,
prostate cancer may lead to reactivation of infection resulting in an
increase in titre of anti-BKV antibodies. We examined the relation
between BK virus antibodies and cancers of the prostate, kidney
and bladder, in plasma collected prior to diagnosis, in a case–
control study nested within the Oxford component of the
European Prospective Investigation into Cancer and Nutrition
(EPIC-Oxford).
MATERIALS AND METHODS
Between 1993 and 1999, 58000 people aged 20 years and above and
living in the UK were recruited into the Oxford component of the
European Prospective Investigation into Cancer and Nutrition (for
further details of the study see: Riboli and Kaaks, 1997; Davey et al,
2003). Recruitment was through collaborating general practi-
tioners, vegetarian and vegan societies, health-food magazines and
from friends and relatives of the participants. Data were obtained
via questionnaire on demographic, diet and other lifestyle factors
and, for 30% of volunteers, a blood sample was taken, sent through
the mail to the laboratory, separated, aliquoted and stored in liquid
nitrogen. All participants are followed up for mortality and cancer
incidence by record linkage with the National Health Service
Central Register. Ethical approval was granted by a Multi-Centre
Research Ethics Committee.
In this study, cases were people with cancers of the prostate
(n¼31), kidney (n¼5) or bladder (n¼9), for whom a plasma
sample was available from prior to diagnosis. For each case, one
control was randomly selected from among other study partici-
pants for whom a plasma sample was available and who had not
been diagnosed with cancer, after matching for age, sex,
geographical location, length of follow-up and date of blood
sampling (71 month).
Plasma samples were shipped on dry ice to the INSERM U618
laboratory in Tours, France, for BKV testing. Assays were performed
by a single investigator (TR), who was blind to the diagnosis of the
relevant patients. BKV VLPs were produced in insect cells using
recombinant baculovirus encoding BKV VP1 protein, and purified
as previously described (Touze ´ et al, 2001). To remove possible
background sero-reactivity, sera were also tested against bovine
serum albumin (BSA). Flat-bottomed wells of 96-well microplates
(Nunc, Life Technologies, Eragny, France) were coated overnight at
41C with 200ng of VLPs or BSA in PBS, pH 7.4. After washing with
PBS, 0.1% Tween 20 and 200ml of PBS containing 1% newborn
bovine serum (NBS, Sigma, St Quentin Favallier, France) were added
(2h at 371C). The blocking solution was replaced by 100mlo fs e r a
diluted 1:100 in 5 PBS-10% NBS and 2% Tween 20, and plates
were incubated at 451C for 60min. After four washes, bound
antibodies were detected with a goat anti-human IgG immunoglo-
bulin (diluted 1:5000) conjugated to horseradish peroxidase
(Sigma). Following incubation at 451C for 1h and four washes,
100ml of a substrate solution containing ortho-phenylenediamine
and H2O2 was added. After 30min incubation, the reaction was
stopped by addition of 100mlo f4 N H2SO4, and optical densities
(OD) were read at 492nm. For each serum sample the background
reactivity found in the BSA-coated wells was subtracted from the OD
found in each of the BKV-VLP coated wells. In addition, titres of
antibodies against BKV were assessed by serial two-fold dilution and
these are the results that are presented here. On the basis of similar
ELISA tests using other recombinant antigens, a result was
considered to be seronegative if the titre of antibodies against
BKV was below 1:100 (Touze ´ et al,1 9 9 9 ) . Received 22 September 2005; accepted 17 October 2005
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(version 7.0; Stata Corp. College Station, TX). Odds ratios (ORs)
for cancer in relation to anti-BKV antibody titres were estimated in
relation to a doubling of titre, with 95% confidence intervals (CI),
using conditional logistic regression. Tests for statistical signifi-
cance of OR were derived from likelihood ratio test statistics. All P-
values are derived from two-sided tests of statistical significance.
RESULTS AND DISCUSSION
The mean time between blood sampling and diagnosis of cancer
was 3.1 years (standard deviation (s.d.) 1.8 years) for prostate
cancer, 2.0 years (s.d. 1.0 years) for renal cancer and 1.4 years (s.d.
1.2 years) for bladder cancer. The prevalence of anti-BKV
antibodies was 91% (41/45) among controls and for people with
cancers of the prostate, kidney and bladder it was 94% (29/31),
100% (5/5) and 78% (7/9), respectively.
For a doubling of anti-BKV antibody titre, the OR was estimated
to change by a multiplicative factor of 0.9 (95% CI 0.6–1.2;
w
2
1¼1.0, P¼0.3) for prostate cancer (31 cases), 1.8 (95% CI 0.5–
7.0; w
2
1¼0.8, P¼0.4) for renal cancer (5 cases) and by 0.8 (95% CI
0.4–1.6; w
2
1¼0.4, P¼0.5) for bladder cancer (9 cases). Figure 1
shows the titre of antibodies against BKV for each participant both
for cases (according to cancer type) and controls.
These results are the first to be reported from a prospective
sero-epidemiological study of BK virus in relation to the risk of
cancers of the prostate, kidney and bladder. We found no evidence
of an association between the prevalence or titre of antibodies
against BKV, measured in plasma taken prior to diagnosis, and any
of the case groups studied, although the number of people with
cancer of the kidney and bladder, in particular, was small. These
findings suggest that the association found in a previous study,
between high anti-BKV antibody titres and prostate cancer
(Newton et al, in press), either arose by chance, or resulted from
reactivation of infection following tumour development.
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Figure 1 A graph showing the distribution of anti-BKV antibody titres for
people with cancers of the prostate, kidney and bladder and for controls in
the EPIC-Oxford cohort.
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